Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 77Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 11Myeloproliferative Disorders 6Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 4Recurrence 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia 3Hematologic Diseases 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2GATA2 Deficiency 2Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vorinostat 1Transplantation 1Tacrolimus 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Cyclophosphamide 1Busulfan 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × Azacitidine × 90 days × Clear all
NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
135 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡